Mycio Wealth Partners LLC Reduces Position in Amgen, Inc. (AMGN)

Mycio Wealth Partners LLC decreased its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 10.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,537 shares of the medical research company’s stock after selling 515 shares during the quarter. Mycio Wealth Partners LLC’s holdings in Amgen were worth $846,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of AMGN. Janus Henderson Group PLC boosted its position in shares of Amgen by 3,664.7% during the second quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock worth $637,139,000 after acquiring an additional 3,601,087 shares during the last quarter. FMR LLC boosted its position in shares of Amgen by 4.8% during the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after acquiring an additional 2,587,041 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Amgen by 40.9% during the second quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock worth $585,607,000 after acquiring an additional 986,700 shares during the last quarter. BlackRock Inc. boosted its position in shares of Amgen by 1.9% during the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after acquiring an additional 909,689 shares during the last quarter. Finally, Nordea Investment Management AB raised its stake in Amgen by 12.9% during the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after purchasing an additional 806,119 shares in the last quarter. Hedge funds and other institutional investors own 78.46% of the company’s stock.

A number of equities research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Royal Bank of Canada decreased their price target on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating on the stock in a research note on Thursday, October 26th. Credit Suisse Group reaffirmed a “neutral” rating and set a $186.00 price target (up previously from $177.00) on shares of Amgen in a research note on Friday, September 29th. Oppenheimer reaffirmed a “buy” rating and set a $203.00 price target on shares of Amgen in a research note on Thursday, September 7th. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $199.00 price target on shares of Amgen in a research note on Monday, September 25th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $190.22.

In other news, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The disclosure for this sale can be found here. In the last three months, insiders sold 8,575 shares of company stock worth $1,509,339. Insiders own 0.19% of the company’s stock.

Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $177.11 on Thursday. Amgen, Inc. has a 12 month low of $145.12 and a 12 month high of $191.10. The firm has a market cap of $129,890.00, a price-to-earnings ratio of 14.00, a PEG ratio of 2.55 and a beta of 1.36. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. During the same quarter in the prior year, the firm posted $3.02 earnings per share. The business’s revenue for the quarter was down .7% on a year-over-year basis. sell-side analysts expect that Amgen, Inc. will post 12.66 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be paid a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.28 annualized dividend and a dividend yield of 2.98%. This is an increase from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio is currently 41.55%.

Amgen declared that its board has approved a stock buyback program on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

ILLEGAL ACTIVITY WARNING: “Mycio Wealth Partners LLC Reduces Position in Amgen, Inc. (AMGN)” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://sportsperspectives.com/2017/12/21/mycio-wealth-partners-llc-reduces-position-in-amgen-inc-amgn.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply